BioSpace News Archive

The foot & ankle devices market was valued at US$ 2,038.24 million in 2018 and it is projected to reach US$ 4,084.97 million in 2027; it is expected to grow at a CAGR of 8.1% from 2019 to 2027.

MorphoSys AG today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended for its tender offer for Constellation Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the second quarter of 2021 on Wednesday, July 28, 2021 at 7:00 a.m. ET.

AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that both the impact factor and immediacy index of its journal Clinical Chemistry have risen to 8.327 and 8.729, respectively, in the 2020 Clarivate Analytics Journal Citation Reports.

A new study entitled “n-6 High Fat Diet Induces Gut Microbiome Dysbiosis and Colonic Inflammation” was released to the public this week, co-authored by Dr. Sabine Hazan, creator of ProgenaBiome, a genetic sequencing research laboratory.

Universal data connectivity for life science laboratories delivers seamless digital ecosystem and full automation of lab workflows – with the goal of accelerating scientific discovery

BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), today announced the appointment of Dave Jenkins as Chief Financial Officer.

Cytokinetics, Incorporated announced that on June 30, 2021 it granted stock options to purchase an aggregate of 90,000 shares of common stock to twelve new employees whose employment commenced in June 2021 as a material inducement to their employment.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the closing of an underwritten public offering of 3,565,000 shares of its common stock at a public offering price of $48.50 per share,

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces positive results from the second interim analysis of POSEIDON, the North American pivotal study of the alfapump for the treatment of recurrent or refractory ascites due to liver cirrhosis.